Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Novo Nordisk ADR (NYSE: NVO) was $53.94 for the day, down -21.83% from the previous closing price of $69.0. In other words, the price has decreased by -$21.83 from its previous closing price. On the day, 110.4 million shares were traded. NVO stock price reached its highest trading level at $55.36 during the session, while it also had its lowest trading level at $53.51.
Ratios:
Our analysis of NVO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.71. For the most recent quarter (mrq), Quick Ratio is recorded 0.56 and its Current Ratio is at 0.74. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.70.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 246822977536 and an Enterprise Value of 383498485760. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.00, and their Forward P/E ratio for the next fiscal year is 11.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.17 while its Price-to-Book (P/B) ratio in mrq is 11.94. Its current Enterprise Value per Revenue stands at 1.265 whereas that against EBITDA is 2.47.
Stock Price History:
The Beta on a monthly basis for NVO is 0.65, which has changed by -0.5933047 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $139.74, while it has fallen to a 52-week low of $57.00. The 50-Day Moving Average of the stock is -23.17%, while the 200-Day Moving Average is calculated to be -35.60%.
Shares Statistics:
NVO traded an average of 9.51M shares per day over the past three months and 18719950 shares per day over the past ten days. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.69% stake in the company. Shares short for NVO as of 1752537600 were 23584063 with a Short Ratio of 2.48, compared to 1749772800 on 26611463. Therefore, it implies a Short% of Shares Outstanding of 23584063 and a Short% of Float of 0.69999998.
Dividends & Splits
With its trailing 12-month dividend rate of 11.4, NVO has a forward annual dividend rate of 1.66. Against a Trailing Annual Dividend Yield of 0.16521738The stock’s 5-year Average Dividend Yield is 1.46. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-03-31 with an ex-dividend date of 2025-03-31. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
The market rating of Novo Nordisk ADR (NVO) is currently shaped by the ongoing analysis conducted by 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $6.41, with high estimates of $6.49 and low estimates of $6.32.
Analysts are recommending an EPS of between $26.36 and $23.1 for the fiscal current year, implying an average EPS of $25.25. EPS for the following year is $28.88, with 8.0 analysts recommending between $30.84 and $25.92.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $80.48B to a low estimate of $74.38B. As of the current estimate, Novo Nordisk ADR’s year-ago sales were $68.06BFor the next quarter, 11 analysts are estimating revenue of $81.6B. There is a high estimate of $86.25B for the next quarter, whereas the lowest estimate is $77.22B.
A total of 22 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $353.05B, while the lowest revenue estimate was $311.81B, resulting in an average revenue estimate of $326.83B. In the same quarter a year ago, actual revenue was $290.4BBased on 21 analysts’ estimates, the company’s revenue will be $372.37B in the next fiscal year. The high estimate is $407.35B and the low estimate is $331.1B.
